ABT-888
Term · Oncology and biomedicine · MLC-T-ONC-000121
A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. ABT-888 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor. Also called PARP-1 inhibitor ABT-888 and veliparib.
| Identifier | MLC-T-ONC-000121 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | PARP-1 inhibitor ABT-888; veliparib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-000121",
"term": "ABT-888",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. ABT-888 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor. Also called PARP-1 inhibitor ABT-888 and veliparib.",
"expansions": [
"PARP-1 inhibitor ABT-888",
"veliparib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/abt-888/"
}
Record 201 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.